This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte's Management Presents At Goldman Sachs Healthcare Conference (Transcript)

So all of those things I think give us the potential to have a differentiated product and we just have to see, we have to be further along with more patients before be able confident saying what they are, that 050 is JAK1, JAK2 inhibitor and the tofa product is more of an pan-JAK inhibitor. Therefore it has JAK3 that may play into. We’re not entirely sure what the value is of the JAK3 component on that and it may have some negatives to it.

But again, all pre-mature. We are generally very pleased with the tofa AdCom. We thought it showed that the drug classes are good and viable, but at the same time left a room for some differentiation and some opportunities to maybe be stronger.

Sapna Srivastava - Goldman Sachs

I guess that ACR, this is a 24-week data. Do you have it in-house by now; I mean just for the feed two different sets of it, like, we’re seeing 12-week now at ULR or is it still….

Pat Andrews

The trial is complete now, but you’ll just see the 12-week data here and the 24-week data, the 6-month data would be at ACR.

Sapna Srivastava - Goldman Sachs

And when can we expect to hear about the safety design, they’re just like from the tofa panel like when do we see the Phase III design of the trial start by the year-end……

Pat Andrews

That’s the expectation, yes and that really would be a communication that Lilly would trigger, so until that point, we don’t have too much color we can provide on the Phase III, other than we know that Lilly is anxious to begin the Phase III trials which as we are.

Sapna Srivastava - Goldman Sachs

And just if we could, on that any questions from the audience on the RA drug?

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs